Stock Scorecard
Stock Summary for Cellectis (CLLS) - $1.59 as of 12/20/2024 3:22:58 PM EST
Total Score
9 out of 30
Safety Score
23 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CLLS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CLLS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CLLS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CLLS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CLLS (23 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 3 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for CLLS
Financial Details for CLLS
Company Overview |
|
|---|---|
| Ticker | CLLS |
| Company Name | Cellectis |
| Country | USA |
| Description | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 1.59 |
| Price 4 Years Ago | 27.06 |
| Last Day Price Updated | 12/20/2024 3:22:58 PM EST |
| Last Day Volume | 87,886 |
| Average Daily Volume | 69,193 |
| 52-Week High | 3.55 |
| 52-Week Low | 1.53 |
| Last Price to 52 Week Low | 3.92% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 125.61 |
| Sector PE | 40.44 |
| 5-Year Average PE | -4.32 |
| Free Cash Flow Ratio | 1.00 |
| Industry Free Cash Flow Ratio | 15.99 |
| Sector Free Cash Flow Ratio | 27.17 |
| Current Ratio Most Recent Quarter | 1.78 |
| Total Cash Per Share | 1.59 |
| Book Value Per Share Most Recent Quarter | 1.29 |
| Price to Book Ratio | 1.23 |
| Industry Price to Book Ratio | 5.62 |
| Sector Price to Book Ratio | 20.63 |
| Price to Sales Ratio Twelve Trailing Months | 4.54 |
| Industry Price to Sales Ratio Twelve Trailing Months | 14.60 |
| Sector Price to Sales Ratio Twelve Trailing Months | 24.53 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 100,094,000 |
| Market Capitalization | 159,149,460 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -2.40% |
| Reported EPS 12 Trailing Months | -1.16 |
| Reported EPS Past Year | -1.21 |
| Reported EPS Prior Year | -1.78 |
| Net Income Twelve Trailing Months | -85,545,000 |
| Net Income Past Year | -101,059,000 |
| Net Income Prior Year | -98,688,000 |
| Quarterly Revenue Growth YOY | 998.00% |
| 5-Year Revenue Growth | -43.16% |
| Operating Margin Twelve Trailing Months | -0.60 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 159,087,000 |
| Total Cash Past Year | 136,708,000 |
| Total Cash Prior Year | 97,697,000 |
| Net Cash Position Most Recent Quarter | 117,979,000 |
| Net Cash Position Past Year | 108,264,000 |
| Long Term Debt Past Year | 28,444,000 |
| Long Term Debt Prior Year | 20,531,000 |
| Total Debt Most Recent Quarter | 41,108,000 |
| Equity to Debt Ratio Past Year | 0.75 |
| Equity to Debt Ratio Most Recent Quarter | 0.76 |
| Total Stockholder Equity Past Year | 84,695,000 |
| Total Stockholder Equity Prior Year | 117,968,000 |
| Total Stockholder Equity Most Recent Quarter | 129,424,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 60,028,001 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.60 |
| Free Cash Flow Past Year | -25,819,000 |
| Free Cash Flow Prior Year | -89,885,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.06 |
| MACD Signal | -0.02 |
| 20-Day Bollinger Lower Band | 1.58 |
| 20-Day Bollinger Middle Band | 2.02 |
| 20-Day Bollinger Upper Band | 2.45 |
| Beta | 3.20 |
| RSI | 33.05 |
| 50-Day SMA | 2.37 |
| 150-Day SMA | 2.59 |
| 200-Day SMA | 5.42 |
System |
|
| Modified | 12/20/2024 9:07:49 PM EST |